Remdesivir^®

Remdesivir is an adenosine nucleotide prodrug that inhibits viral RNA synthesis.

Remdesivir is used for the treatment of COVID-19 in adults and children who require hospitalization, or in outpatients with mild to moderate COVID-19 who are at high risk of progression to severe disease, including hospitalization or death.

100 mg in 20 mL concentrated solution for intravenous infusion.

Remdesivir should be prepared under aseptic conditions immediately before injection.

The Remdesivir solution should show no discoloration and should be free of precipitate or foreign particles.

Remdesivir is compatible for dilution with 0.9% sodium chloride.

The diluted solution prepared by this method is stable for 4 hours at room temperature (20–25°C) or for 24 hours in the refrigerator (2–8°C).

• Remdesivir is for intravenous infusion only. Do not administer it intramuscularly.
• The diluted Remdesivir solution in 0.9% sodium chloride should be infused over 30 to 120 minutes.
• After the infusion is fully completed, continue the infusion with at least 30 mL of 0.9% sodium chloride to flush any remaining medicine from the infusion set.
• Do not mix Remdesivir with other medicines or administer it simultaneously with other medicines.

• Heart rate
• Liver enzymes (ALT, AST, bilirubin, and alkaline phosphatase)
• Kidney function
• Prothrombin time (PT)
• Signs of severe hypersensitivity reactions

Hypersensitivity to Remdesivir or to any component of the formulation.

• To reduce the likelihood of hypersensitivity reactions related to Remdesivir — with symptoms such as changes in blood pressure, increased or decreased heart rate, decreased blood oxygen, fever, breathing difficulty, angioedema, skin rash, nausea, vomiting, sweating, and chills slow infusion is recommended, up to a maximum infusion time of 120 minutes. If these symptoms occur, Remdesivir treatment should be stopped and appropriate supportive measures should be started.
• If ALT increases together with signs of liver inflammation, increased alkaline phosphatase, or increased INR, Remdesivir treatment should be stopped.
• Use this medicine with caution in patients with severe kidney impairment (creatinine clearance below 30 mL/min).

Use of Remdesivir during pregnancy should be based on an assessment of the benefits and risks for the mother and infant.

It is unknown how much Remdesivir is excreted in breast milk or what effects it may have on the infant. Considering the possibility of COVID-19 transmission to the infant and possible adverse effects of the medicine, the specialist physician should decide whether to continue treatment or breastfeeding.

Like all medicines, Remdesivir may cause unwanted side effects along with its desired therapeutic effects, although not everyone experiences them. More common possible side effects include:

• Injection-site irritation
• Increased blood glucose
• Decreased hemoglobin and lymphocyte count
• Cardiac adverse effects
• Liver and kidney adverse effects

Consult your physician or pharmacist about using Remdesivir together with other medicines or supplements.

Each package contains 1 vial of medicine.

• Store at 2–8°C, protected from light and moisture.
• The medicine may be used until the end of the month stated in the expiry date on the package. Do not use or store expired medicines.
• Keep the medicine out of the sight and reach of children.
• Keep the medicine in its original packaging until use.

1. Remdesivir: Drug information, UpToDate 2025
2. Medicines.org.uk product information for Remdesivir.